Abdominal obesity and metabolic syndrome
The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, inflammation, insulin resistance or full-blown diabetes, and increased risk of developing cardiovascular disease. Proposed criteria for identifying patients with metabolic syndrome have contributed greatly to preventive medicine, but the value of metabolic syndrome as a scientific concept remains controversial. The presence of metabolic syndrome alone cannot predict global cardiovascular disease risk. But abdominal obesity - the most prevalent manifestation of metabolic syndrome - is a marker of 'dysfunctional adipose tissue', and is of central importance in clinical diagnosis. Better risk assessment algorithms are needed to quantify diabetes and cardiovascular disease risk on a global scale.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is strongly linked to visceral fat accumulation around abdominal organs, disrupting normal endocrine functions more than subcutaneous fat (Dam et al., 2016; Després & Lemieux, 2006).”
From Long-term cardiometabolic effects of early institutionalization and foster care: Evidence from the Bucharest Early Intervention Project (2026) · cites this paper as Després & Lemieux, 2006
In the citing paper
“Alarmingly, obesity is known to pose a more substantial health hazard than the other CMD risks [19,20,21].”
In the citing paper
“Most tests of Fe status, however, are affected in response to subclinical inflammation and infections (690 -692) .”
From Dietary factors and low-grade inflammation in relation to overweight and obesity (2011) · cites this paper as [691]
In the citing paper
“The results of the present study contradict the prevailing dogma that VAT has deleterious metabolic effects (5,6).”
From Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity (2009) · cites this paper as [6]
In the citing paper
“The metabolic syndrome is a cluster of coronary heart disease risk factors-central obesity, hypertension, dyslipidemia, and glucose intolerance-that share an association with insulin resistance, which appears to be the primary underlying pathophysiologic disturbance (1).”
From Eating Meals Irregularly: A Novel Environmental Risk Factor for the Metabolic Syndrome (2008) · cites this paper as [1]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“In obesity, there is evidence of macrophage infiltration in adipose tissu”
BackgroundPrediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581 · cited 1×
“It has also been argued that current risk-assessment algorithms such as the Framingham Heart Study calculator of coronary heart disease (CHD) ris”
MethodThe metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Research works printed but not linked: 3
- Lemieux, I. et al. Contribution of interleukin-6 and tumor necrosis factor-alpha to the elevated C-reactive protein levels found in abdominally obese men. Obes. Res. 9, 66S (2001).
- Beckley, E. T. New ADA initiative moves beyond 'metabolic syndrome'. 'Cardiometabolic risk' proposed as umbrella term for diabetes risk factors. DOC News 3, 1–3 (2006).
- Després, J. P. From CVD risk to cardiometabolic risk. Presented at the Symposium of the International Chair on Cardiometabolic Risk. XIV International Symposium on Atherosclerosis (Rome, 18–22 June 2006).
Cited by
Items 1,001–1,035 of 1,035
Ramos-Romero, S., Hereu, M., Atienza, L., Casas, J., Jáuregui, O., Amézqueta, S., Dasilva, G., Medina, I., Nogués, M. R., Romeu, M., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2017 · Cited by 52
Wang, J. W., Mark, S., Henderson, M., O'Loughlin, J., Tremblay, A., Wortman, J., Paradis, G., & Gray‐Donald, K. (2013) · Pediatric Obesity · doi:10.1111/j.2047-6310.2012.00108.x · Cited by 51
“In adults, an elevated WC is the most prevalent manifestation of MetS and is associated with increased risk of both type 2 diabetes and cardiovascular disease (65).”
BackgroundSmith, S. R., Stenlof, K. S., Greenway, F. L., McHutchison, J., Schwartz, S. M., Dev, V. B., Berk, E. S., & Kapikian, R. (2011) · Obesity · doi:10.1038/oby.2011.143 · Cited by 51
Mally, K., Trentmann, J., Heller, M., & Dittmar, M. (2011) · European Journal of Applied Physiology · doi:10.1007/s00421-010-1795-x · Cited by 49
Gorgey, A. S., & Gater, D. R. (2011) · PM&R · doi:10.1016/j.pmrj.2011.01.011 · Cited by 48
Searching for a mitochondrial root to the decline in muscle function with ageing
Gonzalez‐Freire, M., Adelnia, F., Moaddel, R., & Ferrucci, L. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12313 · Cited by 48
“Fat accumulation is a phenotypic manifestation of metabolic impairment, especially when fat accumulates in visceral compartments, such as in the abdomen, liver, or muscle.(7) ED ITOR IAL”
BackgroundLechner, K., Lechner, B., Crispin, A., Schwarz, P. E. H., & von Bibra, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-87266-z · Cited by 46
Bernardi, J. R., Ferreira, C. F., Senter, G., Krolow, R., de Aguiar, B. W., Portella, A. K., Kauer-Sant'Anna, M., Kapczinski, F., Dalmaz, C., Goldani, M. Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062031 · Cited by 43
“The increased abdominal fat is suggested as a marker of ’dysfunctional adipose tissue’ [39], leading to altered free fatty acids metabolism, and hypertrigliceridemia as we saw in maternal separated animals.”
BackgroundMetabolic flexibility and obesity in children and youth
Aucouturier, J., Duché, P., & Timmons, B. W. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00812.x · Cited by 43
“Ectopic fat depots such as in the viscera, the skeletal muscle, the liver or the pancreas (13) rather than whole body adiposity are associated with metabolic abnormalities and defects in insulin signalling (13–15).”
BackgroundDe Fano, M., Bartolini, D., Tortoioli, C., Vermigli, C., Malara, M., Galli, F., & Murdolo, G. (2022) · doi:10.20944/preprints202204.0011.v1 · Cited by 41
Casazza, K., Page, G. P., & Fernandez, J. R. (2010) · Biological Research For Nursing · doi:10.1177/1099800410371118 · Cited by 40
“Accumulation in this visceral fat depot can thus induce high levels of free fatty acids in the liver, leading to a cascade of adverse effects on lipid profile and control of blood insulin (Despres & Lemieux, 2006; Pascot et al., 2000).”
BackgroundAssociations of Sedentary Time with Fat Distribution in a High-Risk Population
HENSON, J., EDWARDSON, C. L., MORGAN, B., HORSFIELD, M. A., BODICOAT, D. H., BIDDLE, S. J. H., GORELY, T., NIMMO, M. A., MCCANN, G. P., KHUNTI, K., et al. (2015) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000572 · Cited by 39
“ences in adipose tissue deposition (6).”
BackgroundInfluentialExercise training at maximal fat oxidation intensity for older women with type 2 diabetes
Tan, S., Du, P., Zhao, W., Pang, J., & Wang, J. (2018) · International Journal of Sports Medicine · doi:10.1055/a-0573-1509 · Cited by 39
“This fat depot actively releases non-esterified fatty acid, cytokines and adipokines, which can cause systemic inflammation and metabolic diseases [14, 39].”
BackgroundSavoia, C., Volpe, M., Alonzo, A., Rossi, C., & Rubattu, S. (2010) · Clinical Science · doi:10.1042/cs20090204 · Cited by 35
LeBlanc, S., Coulombe, F., Bertrand, O. F., Bibeau, K., Pibarot, P., Marette, A., Alméras, N., Lemieux, I., Després, J., & Larose, E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008139 · Cited by 35
“Visceral adipose tissue (VAT) is one such important key mediator, influencing glucose metabolism, blood pressure, lipid profile, and inflammatory profile.(5) Even in apparently healthy young adults devoid of traditional risk factors, whether of normal weight or overweight, VAT has been related to a worse cardiometabol…”
Self-citationNelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Jahansouz, C., Serrot, F. J., Frohnert, B. I., Foncea, R. E., Dorman, R. B., Slusarek, B., Leslie, D. B., Bernlohr, D. A., & Ikramuddin, S. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1708-5 · Cited by 32
“One limitation of this study is the use of subcutaneous WAT given evidence suggesting that visceral adipose tissue is perhaps more critical to the development of metabolic disease [44].”
Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling
Mahmut, A., Boulanger, M., Fournier, D., Couture, C., Trahan, S., Pagé, S., Arsenault, B., Després, J., Pibarot, P., & Mathieu, P. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12081 · Cited by 31
Self-citationOxidative Stress Mediates Depot-Specific Functional Differences of Human Adipose-Derived Stem Cells
Sriram, S., Yuan, C., Chakraborty, S., Tay, W., Park, M., Shabbir, A., Toh, S.-A., Han, W., & Sugii, S. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1240-y · Cited by 27
Bagheri, P., Khalili, D., Seif, M., & Rezaianzadeh, A. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00716-7 · Cited by 30
“with the occurrence of other components of the MetS [49, 72].”
BackgroundLipocalin 13 regulation of glucose and lipid metabolism in obesity
Zhou, Y., & Rui, L. (2013) · Vitamins & Hormones · doi:10.1016/b978-0-12-407766-9.00015-8 · Cited by 28
“…well defined that obesity is closely associated with various metabolic diseases, including insulin resistance, type 2 diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease (Despres and Lemieux, 2006; Kahn et al., 2006; Van Gaal et al., 2006).”
BackgroundKlafke, J. Z., Porto, F. G., Batista, R., Bochi, G. V., Moresco, R. N., da Luz, P. L., & Viecili, P. R. N. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.06.013 · Cited by 28
Lévesque, V., Poirier, P., Després, J.-P., & Alméras, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.08.008 · Cited by 25
Self-citationMouchiroud, M., Camiré, É., Aldow, M., Caron, A., Jubinville, É., Turcotte, L., Kaci, I., Beaulieu, M.-J., Roy, C., Labbé, S. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.014 · Cited by 24
“Alterations in liver functions linked to chronic overfeeding and obesity contribute to the development of several health issues including insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular diseases [1,2].”
BackgroundCirculating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women
Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y. (2021) · Nutrients · doi:10.3390/nu13030865 · Cited by 21
“Since IR will lead to a gradual progression from hyperinsulinemia to glucose intolerance and eventually, T2D [10], the early detection of MetS risks (including IR) is important for the prevention of chronic metabolic diseases [9].”
BackgroundInfluentialLuotola, K., Piltonen, T. T., Puurunen, J., Morin-Papunen, L. C., & Tapanainen, J. S. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1342793 · Cited by 21
“Adipose tissue plays a central role in subclinical inflammation, which has been observed in cases of PCOS [1,11] and is associated with abdominal obesity and metabolic disturbances [18].”
BackgroundMartens, E. A., Gatta-Cherifi, B., Gonnissen, H. K., & Westerterp-Plantenga, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109617 · Cited by 21
“Visceral adipose tissue (VAT) volume has been linked to the metabolic disturbances associated with obesity, such as a diminished insulin sensitivity and dyslipidemia [6].”
BackgroundValidation of a free software for unsupervised assessment of abdominal fat in MRI
Maddalo, M., Zorza, I., Zubani, S., Nocivelli, G., Calandra, G., Soldini, P., Mascaro, L., & Maroldi, R. (2017) · Physica Medica · doi:10.1016/j.ejmp.2017.04.002 · Cited by 17
Extracellular vesicle therapy for obesity-induced NAFLD: a comprehensive review of current evidence
Zhang, J., Ma, B., Wang, Z., Chen, Y., Li, C., & Dong, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01292-0 · Cited by 17
“Obesity can lead to a series of metabolic syndromes such as type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), dyslipidemia, inflammation, hyperglycemia, and hypertension [1].”
BackgroundAssociation of body roundness index with female infertility: 2013–2018 NHANES
Wang, W., Hou, S., Wang, K., Ling, B., & Yu, H. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1416637 · Cited by 12
“Abdominal obesity, characterized by fat accumulation around visceral organs in the abdominal cavity, is a prevalent issue linked to infertility (6, 7).”
Resveratrol Inhibits Human Visceral Preadipocyte Proliferation and Differentiation in vitro
Sun, W., Yu, S., Han, H., Yuan, Q., Chen, J., & Xu, G. (2019) · Lipids · doi:10.1002/lipd.12196 · Cited by 11
Porchia, L. M., Vazquez-Marroquin, G., Ochoa-Précoma, R., Pérez-Fuentes, R., & Gonzalez-Mejia, M. E. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-022-01135-0 · Cited by 10
“Under normal dietary conditions, SAT is considered an “energy sink”, that when flooded with energy, typically in the forms of sugars, free fatty acids, triglycerides, and amino acids, is overwhelmed, allowing VAT to develop [57, 58].”
BackgroundComeglio, P., Sarchielli, E., Filippi, S., Cellai, I., Guarnieri, G., Morelli, A., Rastrelli, G., Maseroli, E., Cipriani, S., Mello, T., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01522-7 · Cited by 7
Bigford, G. E., Betancourt, L. F., Charlifue, S., & Nash, M. S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20196819 · Cited by 4
Mens, M. M. J., Jopling, E., Hare, M., Drury, S. S., Nelson, C. A., Zeanah, C. H., Fox, N. A., & Slopen, N. (2026) · Development and Psychopathology · doi:10.1017/s0954579426101540 · Cited by 1
“It is strongly linked to visceral fat accumulation around abdominal organs, disrupting normal endocrine functions more than sub-cutaneous fat (Dam et al., 2016; Després & Lemieux, 2006).”
Metadata
- Authors
- Després, J.-P., & Lemieux, I.
- Venue
- Nature
- Published
- 2006-12-13
- Volume
- 444
- Issue
- 7121
- Pages
- 881-887
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1991334358
- Semantic Scholar
- 12903a24428f6c6024aed0c7b8de08306f8b15ff
- Cited by
- 4,354
- References
- 94
- Citations by year
- 2026: 146 · 2025: 172 · 2024: 216 · 2023: 209 · 2022: 259 · 2021: 259 · 2020: 223 · 2019: 231 · 2018: 236 · 2017: 225 · 2016: 265 · 2015: 236 · 2014: 270 · 2013: 269 · 2012: 241
- FWCI
- 21.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- abdominal obesity, metabolic syndrome, insulin resistance, diabetes risk, cardiovascular risk, inflammation, risk assessment algorithm, diagnostic criteria
- MeSH terms
- Abdomen, Cardiovascular Diseases, Humans, Obesity, Risk Assessment, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.